Equillium (EQ) Liabilities and Shareholders Equity (2017 - 2026)
Equillium's (EQ) quarterly Liabilities and Shareholders Equity came in at $63.1 million in Q1 2026, up 277.09% year-on-year from $16.7 million in Q1 2025, and up 97.83% on a QoQ basis from $31.9 million in Q4 2025.
Equillium (EQ) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Equillium (EQ) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $63.1 million in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 277.09% year-over-year to $63.1 million in Q1 2026; TTM through Mar 2026 was $141.9 million, a 18.57% increase from a year earlier, with the FY2025 full-year figure at $31.9 million, up 24.54% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $63.1 million, up from $31.9 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for EQ reached as high as $71.8 million in Q1 2023 and fell as low as $12.4 million in Q2 2025.
- Historically, Liabilities and Shareholders Equity has averaged $38.8 million across 5 years, with a median of $34.5 million in 2025.
- Across the five-year window, Liabilities and Shareholders Equity tumbled 78.43% in 2022 and jumped 277.09% in 2026, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $23.0 million in 2022, then soared by 119.23% to $50.5 million in 2023, then tumbled by 49.33% to $25.6 million in 2024, then rose by 24.54% to $31.9 million in 2025, then jumped by 97.83% to $63.1 million in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $63.1 million in Q1 2026, $31.9 million in Q4 2025, and $34.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 78.88 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 33.89 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 8.55 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.25 Bn |
| 10 | Equillium | 242.14 Mn | 242.14 Mn | - | 63.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.08 Mn |
| Dec 31, 2025 | 31.89 Mn |
| Sep 30, 2025 | 34.51 Mn |
| Jun 30, 2025 | 12.40 Mn |
| Mar 31, 2025 | 16.73 Mn |
| Dec 31, 2024 | 25.60 Mn |
| Sep 30, 2024 | 34.46 Mn |
| Jun 30, 2024 | 42.86 Mn |
| Mar 31, 2024 | 43.60 Mn |
| Dec 31, 2023 | 50.53 Mn |
| Sep 30, 2023 | 55.23 Mn |
| Jun 30, 2023 | 58.76 Mn |
| Mar 31, 2023 | 71.79 Mn |
| Dec 31, 2022 | 23.05 Mn |
| Sep 30, 2022 | 48.63 Mn |
| Jun 30, 2022 | 23.05 Mn |
| Mar 31, 2022 | 23.05 Mn |
| Dec 31, 2021 | 85.41 Mn |
| Sep 30, 2021 | 92.47 Mn |
| Jun 30, 2021 | 99.84 Mn |